Literature DB >> 23269982

Reply to "role of rpsA gene sequencing in diagnosis of pyrazinamide resistance".

David C Alexander1, Jennifer H Ma, Jennifer L Guthrie, Joanne Blair, Pam Chedore, Frances B Jamieson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23269982      PMCID： PMC3536205          DOI： 10.1128/JCM.02760-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  6 in total

1.  The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Yanlin Zhao; Xingshan Cai; Chunming Luo; Cairong Zou; Xin Liu
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

Review 3.  Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings.

Authors:  Gemeda Abebe; Fabienne Paasch; Ludwig Apers; Leen Rigouts; Robert Colebunders
Journal:  J Microbiol Methods       Date:  2010-12-01       Impact factor: 2.363

Review 4.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

5.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

6.  Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.

Authors:  David C Alexander; Jennifer H Ma; Jennifer L Guthrie; Joanne Blair; Pam Chedore; Frances B Jamieson
Journal:  J Clin Microbiol       Date:  2012-08-15       Impact factor: 5.948
  6 in total
  4 in total

Review 1.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

2.  A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.

Authors:  S M Ramirez-Busby; T C Rodwell; L Fink; D Catanzaro; R L Jackson; M Pettigrove; A Catanzaro; F Valafar
Journal:  Sci Rep       Date:  2017-06-19       Impact factor: 4.379

3.  Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance.

Authors:  Aamir Mehmood; Muhammad Tahir Khan; Aman Chandra Kaushik; Anwar Sheed Khan; Muhammad Irfan; Dong-Qing Wei
Journal:  Front Bioeng Biotechnol       Date:  2019-12-10

4.  Pyrazinamide resistance of novel mutations in pncA and their dynamic behavior.

Authors:  Arif Ali; Muhammad Tahir Khan; Abbas Khan; Sajid Ali; Sathishkumar Chinnasamy; Khalid Akhtar; Athar Shafiq; Dong-Qing Wei
Journal:  RSC Adv       Date:  2020-09-28       Impact factor: 4.036
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.